Mavenir and HCL Collaborate on Integration and Delivery of O-RAN Compliant Radios
14.10.2021 16:00:00 EEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced a strategic partnership with HCL Technologies (HCL), a leading global technology company with expertise in network systems testing. This partnership helps accelerate the market availability of O-RAN split 7.2 compliant Remote Radiohead Units (RRUs) while establishing a business model to meet the growing demand and evolving requirements for O-RAN RRUs.
Today’s RRU ecosystem has expanded to offer Communication Service Providers (CSPs) a significantly wider choice of 2G, 3G, 4G, 5G, massive MIMO (mMIMO), millimeter Wave (mmWave), small cell and indoor radios. In turn, the number of RRU partners that Mavenir works with continues to grow, with each partner releasing new and sophisticated radios, with new software, across different radio technologies, output power, antenna dimensions and spectrum to meet the evolving needs of O-RAN customers.
The collaboration brings together HCL’s platform for third-party RRU testing and Mavenir’s full Centralized Unit (CU) and Distributed Unit (DU) RAN software stacks. RRU vendors will, as a result, be given the ability to work directly with HCL to assess their O-RAN interfaces and integrate with Mavenir’s O-RAN compliant cloud-native CU/DU software.
By simplifying testing and validation across multiple O-RAN interoperability profiles, the collaboration will help vendors fast-track validation of frequency variants and the increasingly diverse RRU offerings being demanded by the O-RAN market.
This partnership will benefit both RRU vendors and CSPs by supporting the continued expansion of the radio ecosystem and helping to establish a self-sustaining RRU business model:
- Vendors will be able to rapidly validate their O-RAN compliant RRUs as they develop portfolios of products targeted at different deployment scenarios.
- CSPs will be able to more easily identify the available O-RAN compliant RRU options for specific use cases and locations.
“We are directly addressing requests from customers and partners to speed the integration of new RRU products. The growing scale of the O-RAN industry now demands such a model. And thanks to O-RAN and open interfaces, new players such as HCL can enter the market to effectively serve the market needs,” said Mavenir’s Puneet Sethi, SVP/GM RAN Business Unit. “As more O-RAN RRU products become available and RRU partners are enabled to respond rapidly to their customers, CSPs worldwide will be able to take advantage of the full range of their spectrum assets and benefit from the rapidly accelerating RRU ecosystem.”
“The Mavenir-HCL partnership helps accelerate the O-RAN market, bringing a new suite of product offerings to CSPs and enterprises alike. This sets the stage for a nascent ecosystem accelerating future innovation across key verticals on a global scale,” said HCL’s Rajiv Shesh, Corporate Vice President, Engineering and R&D Services. “HCL is bringing together many decades of network testing experience, 5G expertise, state of the art lab facilities and advanced automation tools to validate the interoperability between Mavenir and RRU partners. HCL provides the necessary visibility and reporting capability that enables operators and enterprises in deploying best-of-breed Mavenir O-RAN solutions.”
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry’s only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211014005064/en/
Contact information
Maryvonne Tubb
Mavenir
PR@mavenir.com
Casey Bush
GlobalResultsPR (US)
mavenir@globalresultspr.com
Kevin Taylor
GlobalResultsPR (EMEA)
mavenir@globalresultspr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corient Accelerates European Growth With the Addition of Letus Private Office30.6.2026 08:15:00 EEST | Press release
Corient today announced an agreement to acquire Letus Private Office (“Letus”), an independent multi-family office and wealth advisory firm serving entrepreneurs, founders and other ultra-high-net-worth individuals and families across France and Europe. The acquisition, subject to closing, builds on recent transactions that have made Corient the world’s largest multi-family office and non-bank wealth manager focused on ultra-high-net worth and high-net-worth clients. Paris-based Letus was founded in 2016 and is led by Managing Partners Anice Chlagou, Stephen Lasry and Alexandre Tsouli, and Partner Sacha Levy. It manages and administers approximately €4.1 billion (about US$5 billion). Letus serves ultra-high-net worth clients, primarily entrepreneurs and their families, providing comprehensive, bespoke services that integrate all aspects of wealth management and family office functions, including investment management, wealth and estate planning, financing, legal and tax support, and ph
Hengrui’s Heng Yi ® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease30.6.2026 08:00:00 EEST | Press release
Hengrui Pharma, a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH (“Novaliq”), a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique EyeSol® water-free platform technology, announce today that on June 23, 2026, the China National Medical Products Administration (NMPA) has approved Heng Yi® (0.1% cyclosporine ophthalmic solution) for the treatment of patients with dry eye disease, aiming to increase tear secretion in patients with reduced tear production and improve the sign of the disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629052295/en/ Heng Yi Heng Yi® is the first and only water-free 0.1% cyclosporine ophthalmic solution and the second dry eye disease drug product approved in China based on the EyeSol® platform technology, following the approval of Heng Qin® (perfluorohexyloctane ophthalmic solution) in 202
“BOCCHI THE ROCK!” SeisyunComplex Premiered on June 20!30.6.2026 08:00:00 EEST | Press release
The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260625185578/en/ We are pleased to announce that the first screening of “BOCCHI THE ROCK!” SeisyunComplex, a new projection mapping work inspired by the highly popular anime “BOCCHI THE ROCK!”, was held on Saturday, June 20. Following its premiere, the work will be screened throughout the year as part of the weekday and weekend lineup of “TOKYO Night & Light”. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.4 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivat
Nebex Raises $30M Seed Round Led by GV to Build Market Infrastructure for the Global Space Economy29.6.2026 18:38:00 EEST | Press release
Nebex, the market infrastructure platform for the global space economy, announced a $30M seed investment led by GV (Google Ventures), with participation from other top-tier venture funds. The company also announced a banking relationship with J.P. Morgan. The capital raise and new banking relationship will help Nebex scale its platform and connect sovereign space programs with the founders and companies building new technologies to serve the space industry. "We built Nebex because we've seen firsthand that ambitious space founders struggle to deliver complex sovereign programs due to the lack of capital markets infrastructure that supports revenue and cashflow. This is something that exists in nearly every other industry," said Tejpaul Bhatia, CEO of Nebex. "Support from these organizations gives Nebex the additional leverage and financial infrastructure to build the global space economy at the scale it demands.” Since its inception, the space industry has run on a closed loop with a h
Medisca Enters Its Next Chapter Under Founder Antonio Dos Santos29.6.2026 17:19:00 EEST | Press release
For more than 35 years, Dos Santos has helped shape Medisca into a global leader in pharmaceutical compounding. As Chief Executive Officer, he will lead the company's long-term strategy, with a focus on expanding Medisca's global reach, investing in new areas of growth, strengthening strategic partnerships, and continuing to advance the products, services, education, and expertise that healthcare professionals rely on every day. "When I founded Medisca, my vision was to raise the standard of pharmaceutical compounding by bringing pharmaceutical-grade quality to the industry and giving healthcare professionals access to the products, knowledge, and innovation they needed to deliver better patient care," said Antonio Dos Santos, Founder and Chief Executive Officer of Medisca. "That purpose continues to guide us. As we begin this next chapter, we'll keep investing in our people, our partnerships, and the innovation that will help shape the future of Medisca and the pharmaceutical compound
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom